Nifty Pharma index rises 2% as Sun Pharma, Lupin receive USFDA approval
Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-angle Glaucoma or Ocular Hypertension.
)
premium
The revenue from operations declined to ~69.7 bn for the fourth quarter against ~71.3 bn during the same period last year
Shares of pharmaceutical companies were in focus with the Nifty Pharma index rising over 2 per cent to 10,623.60 levels in the intra-day deals after Sun Pharmaceutical Industries (Sun Pharma) and Lupin USFDA approval for their respective medicines.